

Reuters to make documentary on Paras Biopharmaceuticals Finland – Innovations in Biologics: Insights of a leading expert

Paras Biopharmaceuticals is proud to announce that Reuters has selected Finland-based company, working on biologics manufacturing & innovations in healthcare

OULU, FINLAND, May 7, 2019 /EINPresswire.com/ -- Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected our Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions.

The documentary is part of their 'Global Thought Leaders' series that will feature some of the world's leading innovators, discussing how their industries/markets are evolving through the use of their latest technologies.



Paras Biopharmaceuticals Logo



Reuters.com

Paras Biopharmaceuticals Finland Oy has developed innovative manufacturing technologies, namely Diabrid[®], NobleClev[®] & Biomultifold[®] technologies which enables the economical production of complex biologics & long therapeutic peptides. Based on its innovations, the company has developed an important biologics and biosimilar products pipeline including a Romiplostim Biosimilar (for ITP), an Osteoporosis drug & a IL1-RA for multiple diseases.

Using its unique production technologies, Paras Biopharmaceuticals Finland Oy also provides contract development & manufacturing services ([CDMO](#)) & bioprocess [enzymes](#) to help bring affordable healthcare solutions for new medicines.

About Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company that started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals' team has strong experience in developing biologics in the most efficient manner.

Company main activities & offerings are in 3 major areas:

1. Contract development & microbial biologics manufacturing (CDMO).
2. Development & Licensing of [Biosimilars](#).
3. Recombinant Bioprocess Enzymes – TEV protease and Recombinant Enterokinase.

Paras Biopharmaceuticals has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft² and a classified cleanroom of 4,300 ft², other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.

Paras Biopharmaceuticals has developed and is now offering clinical development and marketing collaboration for the following Biosimilars: Recombinant Teriparatide, Recombinant Anakinra (Kineret[®] Biosimilar), Recombinant Rasburicase and Recombinant Romiplostim (Nplate[®] Biosimilar).

Kineret[®] and Nplate[®] are registered trademarks of Amgen Inc.

For further details, visit the following website: www.parasbiopharma.com

For further information, please contact:

Paras Biopharmaceuticals Finland Oy

Media Relations & Information

Dr Mark Jackson Tel: +358 442709462 / Email: mark.jackson@parasbiopharma.com
Penny Härkönen Tel: +358442709462 / Email: penny.harkonen@parasbiopharma.com

Mark Jackson
Paras Biopharmaceuticals Finland Oy
+358442905993
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.